Navigation Links
Fish Oil does not Appear to Protect Against Abnormal Heart Rhythms

CHICAGO - Patients with an implantable cardioverter defibrillator did not have a significantly lower risk of serious abnormal heart rhythms// or death by consuming fish oil supplements, which had been thought to have a protective effect, according to a study in the June 14 issue of JAMA.

Sudden cardiac death is responsible for approximately 50 percent of all death from cardiovascular disease in the Western world. Epidemiological studies indicate that intake of very-long-chain n-3 polyunsaturated fatty acids (omega-3 PUFAs) as present in fish or fish oil is associated with a reduction in cardiovascular death, possibly by reducing susceptibility to cardiac arrhythmia, according to background information in the article. Recent trials on fish oil and ventricular arrhythmia (abnormal heart rhythm) in patients with implantable cardioverter defibrillators (ICDs; an electrical device that can correct an abnormal heart rhythm) yielded inconclusive results.

Ingeborg A. Brouwer, Ph.D., of Wageningen University, the Netherlands, and colleagues tested the effect of omega-3 PUFAs from fish on the incidence of recurrent ventricular arrhythmia and all-cause death in a large, placebo-controlled, randomized trial of patients with ICDs. The Study on Omega-3 Fatty acids and ventricular Arrhythmia (SOFA) was conducted at 26 cardiology clinics across Europe and included 546 patients with ICDs and prior documented ventricular tachycardia (VT) or ventricular fibrillation (VF) (both are types of serious cardiac arrhythmias). Patients were randomly assigned to receive 2 grams/day of fish oil in capsules (n = 273) or placebo capsules (n = 273) for a median (midpoint) period of 356 days.

In total, 75 patients (27 percent) in the fish oil group and 81 patients (30 percent) in the placebo group received appropriate ICD intervention for VT or VF. Event-free survival did not substantially improve in the fish oil group.

"In this large randomized trial we did not find evidence of strong protective effect of intake of omega-3 PUFAs from fish oil against ventricular arrhythmia in patients with ICDs. In contrast to others, we did not find that fish oil may have proarrhythmic properties," the authors conclude.


'"/>




Related medicine news :

1. GlaxoSmithKline - Changes Lamictal(R) Label Appearance and Packaging
2. Heart Disease Sign Appears Early in Life
3. With More Appearance Conscious Consumers The Need For Slimming Products Is Rapidly Rising
4. Men Easy To Satisfy Than the Opposite Sex In Terms Of Physical Appearance
5. Grapefruit Aroma Makes Women Appear Younger
6. Bird Flu Appears In Nigeria
7. Appearance Of Facial Scars Improved By Botulinum Toxin
8. Testosterone Replacement Therapy Appears Safe for Prostate
9. Sleep Problems in Overweight Children Appear Fairly Common
10. Breast Cancer Stem Cells Appear Resistant to Radiation Therapy
11. Skin-Destroying Ulcer Appears in NSW as New Treatment Guidelines Emerge
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/21/2017)... ... ... staff at Palm Beach Face is proud to announce that their practice founder, Michael ... take place on April 23rd, the London Marathon has a long tradition of raising funds ... team EMPOWER, raising money for the international charity, Smile Train. , Started in ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Chicago plastic ... the removal of osteoma. An osteoma is a benign bony lump located on the ... eye and can cause difficulties with sight and pain. Dr. Shah has discovered an ...
(Date:4/21/2017)... ... , ... Brady (NYSE:BRC), a global leader in industrial and safety ... vinyl label materials received certification for the BS5609 British Marine Standard. This internationally ... legible, for use on chemical drums shipped by sea. , “Achieving BS5609 ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Dudnyk has ... identity emphasizes the agency’s conviction that the full potential of specialty and orphan brands ... equally appreciated and aligned. , “The Unifying Effect is at the heart of ...
(Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, Patient ... Award in recognition of her extraordinary contributions to the field of patient advocacy ... Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
Breaking Medicine Technology: